An expanded access study of revumenib
Latest Information Update: 28 Jul 2023
At a glance
- Drugs Revumenib (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
Most Recent Events
- 28 Jul 2023 New trial record